We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Arrowhead Pharmaceuticals Inc | NASDAQ:ARWR | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.34 | 1.63% | 21.18 | 20.50 | 21.16 | 21.25 | 20.62 | 20.95 | 1,038,349 | 00:44:04 |
Conference Call and Webcast Today at 4:30 p.m. EDT
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2016 third quarter ended June 30, 2016. The company is hosting a conference call at 4:30 p.m. EDT to discuss results.
Conference Call and Webcast Details
Investors may access a live audio webcast on the Company's website at http://ir.arrowheadpharma.com/events.cfm. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and enter Conference ID 57990579.
A replay of the webcast will be available on the company’s website approximately two hours after the conclusion of the call and will remain available for 90 days. An audio replay will also be available approximately two hours after the conclusion of the call and will be available for 3 days. To access the audio replay, dial 404-537-3406 and enter Conference ID 57990579.
Fiscal 2016 Third Quarter and Recent Company Highlights
Corporate Events
ARC-520
ARC-521
ARC-AAT
Platform and Early Pipeline
Selected Fiscal 2016 Third Quarter Financial Results
ARROWHEAD PHARMACEUTICALS, INC. CONSOLIDATED CONDENSED FINANCIAL INFORMATION (unaudited) Three Months EndedJune 30,
Nine Months EndedJune 30,
OPERATING SUMMARY
2016 2015 2016 2015 REVENUE $ 39,583 $ 123,750 $ 127,083 $ 338,250 OPERATING EXPENSES Research and development 9,423,195 7,490,400 29,782,854 36,877,925 Acquired in-process research and development - - - 10,142,786 Salaries and payroll-related costs 4,113,262 3,570,531 12,281,841 10,262,799 General and administrative expenses 2,275,628 1,829,393 8,045,571 5,612,219 Stock-based compensation 2,750,785 2,486,074 7,547,967 6,706,009 Depreciation and amortization 818,200 741,058 2,416,461 1,480,656 TOTAL OPERATING EXPENSES 19,381,070 16,117,456 60,074,694 71,082,394 OPERATING LOSS (19,341,487 ) (15,993,706 ) (59,947,611 ) (70,744,144 ) OTHER INCOME/(EXPENSE), PROVISION FOR INCOME TAXES (79,256 ) 57,653 446,595 3,546,398 NET LOSS $ (19,420,743 ) $ (15,936,053 ) $ (59,501,016 ) $ (67,197,746 ) EARNINGS PER SHARE (BASIC AND DILUTED): $ (0.32 ) $ (0.27 ) $ (1.00 ) $ (1.19 ) WEIGHTED AVERAGE SHARES OUTSTANDING 59,966,955 59,492,867 59,764,129 56,631,297FINANCIAL POSITION SUMMARY
June 30, September 30, 2016 2015 CASH AND CASH EQUIVALENTS 43,616,543 81,214,354 SHORT-TERM INVESTMENTS 1,030,556 17,539,902 TOTAL CASH RESOURCES (CASH, CASH EQUIVALENTS AND INVESTMENTS) 44,647,099 98,754,256 OTHER ASSETS 40,886,397 33,513,658 TOTAL ASSETS 85,533,496 132,267,914 TOTAL LIABILITIES 26,108,330 22,646,280 TOTAL STOCKHOLDERS' EQUITY 59,425,166 109,621,634 TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY 85,533,496 132,267,914 SHARES OUTSTANDING 60,429,405 59,544,677 PROFORMA SHARES OUTSTANDING (INCLUDING CONVERSION OF PREFERRED SHARES) 63,100,395 62,215,667About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. The company’s pipeline includes ARC-520 and ARC-521 for chronic hepatitis B virus infection, ARC-AAT for liver disease associated with alpha-1 antitrypsin deficiency, ARC-F12 for hereditary angioedema and thromboembolic disorders, ARC-LPA for cardiovascular disease, and ARC-HIF2 for renal cell carcinoma.
For more information please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
DYNAMIC POLYCONJUGATES is a trademark of Arrowhead Pharmaceuticals, Inc.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160809005558/en/
Arrowhead Pharmaceuticals, Inc.Vince Anzalone, CFA626-304-3400ir@arrowheadpharma.comorInvestor Relations:The Trout GroupChad Rubin646-378-2947ir@arrowheadpharma.comorMedia:Russo PartnersMatt Middleman, M.D.212-845-4272matt.middleman@russopartnersllc.com
1 Year Arrowhead Pharmaceuticals Chart |
1 Month Arrowhead Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions